Nsclc

Policy Issue Brief

National Senior Citizens Law Center www.nsclc.org nsclc@nsclc.org 1444 Eye St., NW, Suite 1100 Washington, DC 20005 202-289-6976 • Fax: 202-289-7224 3435 Wilshire Blvd., Suite 2860 Los Angeles, CA 90010 213-639-0930 • Fax: 213-639-0934 1330 Broadway, Suite 525 Oakland, CA 94612 510-663-1055 ...

www.nsclc.org

building an integrated Appeals system for Dual eligibles

issue brief • OctOber 2011 building an integrated Appeals system for Dual eligibles by Georgia burke and Kevin Prindiville NAtiONAl seNiOr citizeNs lA w ceNter • www.Nsclc.

www.nsclc.org

New Targets in Advanced NSCLC: EML4-ALK

Clinical Advances in Hematology & Oncology Volume 9, Issue 3 March 2011 207 New Targets in Advanced NSCLC: EML4-ALK Adam S. Crystal, MD, PhD, and Alice T. Shaw, MD, PhD Dr. Crystal is a Clinical Fellow in Oncology and Dr. Shaw is an Assistant Professor of Medicine at the Massachusetts General ...

www.clinicaladvances.com

KRAS Mutation Analysis in Non-Small Cell Lung Cancer (NSCLC)

KRAS Mutation Analysis in Non-Small Cell Lung Cancer (NSCLC) Policy Number: 2.04.55 Last Review: 9/2011 Origination: 1/2011 Next Review: 5/2012 Policy BCBSKC will not provide coverage for KRAS mutation analysis in non-small cell lung cancer (NSCLC) This is considered investigational.

www.bcbskc.com

Mer and Axl receptor tyrosine kinases are novel therapeutic ...

Mer and Axl receptor tyrosine kinases are novel therapeutic targets in NSCLC Rachel M.A. Linger 1 , Deryck H.G. Middleton 2, Justine Migdall 1, Rebecca A Cohen 1, Atul Mehta 1, Grace K Kim 1, Wilbur A Franklin 2, Daniel T Merrick 2, Xiayuan Liang 2, Paul Jedlicka 2, Lynn E Heasley 3, and Douglas ...

www.lungcancerresearchfoundation.org

Personalized medicine comes to “NSCLC”: 2011 Thoracic ...

Personalized medicine comes to “NSCLC”: 2011 . Vincent A. Miller, M.D. Thoracic Oncology Service Memorial Sloan Kettering Cancer Center

www.syntapharma.com

EGF AND HYPOXIA-INDUCED EXPRESSION OF CXCR4 ON NON-SMALL CELL ...

egf and hypoxia-induced expression of cxcr4 on non-small cell lung cancer cells is regulated by the pi3-kinase/pten/akt/mtor signaling pathway and

www.jbc.org

Tarceva: prolonging survival in second-line advanced NSCLC

tablets Proventoprolong survival ® Tarceva: prolonging survival in second-line advanced NSCLC Tarceva monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen.

www.tarceva.com

Clinical Practice Guideline Update on Chemotherapy for

Clinical Practice Guideline Clinical Practice Guideline Update on Chemotherapy for St IVN Sll CllL Stage IV Non-Small Cell Lung Cancer Stage IV NSCLC slide set.

www.asco.org

News Release Contact: Heather Hatfield 781-681-2124

non-small cell lung cancer (NSCLC) who have had a response or stable disease after at least two cycles of platinum-based chemo-radiotherapy. The study will involve more than 1,300 patients in approximately 30 countries.

www.emdserono.com

Other sites you could try:

Find videos related to Nsclc